All In Biotech

Drug Trial Radar · NCT03903939

Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure

Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/Kilogram(kg)/Minute(Min)) in Trauma Patients With Haemorrhagic Shock Induced Endotheliopathy.

Last checked: Nov 20, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

228

Actual

Start

May 22, 2019

Primary completion

Nov 14, 2021

Study completion Nov 14, 2021

Sponsor

Lead sponsor
Pär JohanssonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Odense University Hospital; Aarhus University Hospital; Aalborg University Hospital; Oslo University Hospital
First posted
Apr 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized (1:1, iloprost: placebo), placebo controlled, blinded, investigator-initiated phase 2b trial in trauma patients with haemorrhagic shock and shock induced endotheliopathy (SHINE), investigating the efficacy and safety of continuous intravenous administrating of iloprost (1 ng/kg/min) versus placebo for 72-hours, in a total of 220 patients. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in trauma patients with haemorrhagic shock (SHINE) suffering from organ failure caused by endothelial breakdown, ultimately improving survival.

Conditions

  • Multi Organ Failure

Interventions

  • IloprostDrug

    continuously infusion for 72 hours 1 ng/kg/min

  • Isotonic salineDrug

    continuously infusion for 72 hours equal volume to Iloprost

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ICU free daysTime frame: 28 days after admission

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Rigshospitalet (University of Copenhagen)

    Copenhagen, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Oslo University Hospital

    Oslo, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.